🇺🇸 FDA
Pipeline program

Garetosmab

R2477-FOP-2175

Phase 3 small_molecule active

Quick answer

Garetosmab for Fibrodysplasia Ossificans Progressiva is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Fibrodysplasia Ossificans Progressiva
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials